加巴喷丁治疗妊娠剧吐的双盲随机对照试验
这项双盲随机多中心试验纳入31例医学难治性妊娠剧吐患者,比较口服加巴喷丁与昂丹司琼或甲氧氯普胺的疗效。结果显示,加巴喷丁组在第5至7天PUQE总分下降幅度比对照组高52%(95%CI 16-88,P=.01),多数次要结局也倾向加巴喷丁,不良事件两组相当。
要点
- 加巴喷丁组第5-7天基线调整后PUQE总分降幅较对照组高52%(95%CI 16-88,P=.01)。
- 恶心和干呕/呕吐子评分分别多降46%和49%,口服营养评分多增96%。
- 总体治疗满意度差异为254%(95%CI 48-459,P=.03),不良事件两组相当。
核心结论
- 在这项小样本试验中,加巴喷丁在减少恶心呕吐、改善口服营养和总体满意度方面优于标准治疗。
研究设计与样本
- 双盲、随机、多中心试验,纳入31例需静脉补液的医学难治性妊娠剧吐患者,按1:1随机分入口服加巴喷丁组(1800-2400 mg/d)或活性对照组(昂丹司琼24-32 mg/d或甲氧氯普胺45-60 mg/d),疗程7天。
主要发现
- 加巴喷丁组第5至7天基线调整后PUQE总分降幅较活性对照组高52%(95%CI 16-88;P=.01)。
- 加巴喷丁组基线调整后恶心子评分多降46%(95%CI 19-72;P=.005),干呕/呕吐子评分多降49%(95%CI 21-77;P=.005)。
- 加巴喷丁组基线调整后口服营养评分多增96%(95%CI 27-165;P=.01),总体治疗满意度差异为254%(95%CI 48-459;P=.03)。
- 缓解(P=.06)和继续治疗意愿(P=.06)呈倾向加巴喷丁的趋势,但NVP生活质量(P=.68)和妊娠剧吐终止妊娠考虑(P=.58)组间无差异。
- 不良事件两组大致相当,无严重不良事件。
关键数值与推荐
- 主要终点为第5至7天平均PUQE总分,采用意向性分析、线性混合效应模型调整基线PUQE评分。
- 多重比较采用错误发现率校正。
临床怎么用
- 对于需静脉补液的医学难治性妊娠剧吐门诊患者,加巴喷丁可能作为改善恶心呕吐和口服营养的治疗选择。
- 本研究样本量小,结果需进一步研究验证后方可常规推广。
局限性
- 样本量小,仅21例提供主要结局数据(加巴喷丁组12例,对照组9例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperemesis gravidarum is a disabling disease of nausea, vomiting, and undernutrition in early pregnancy for which there are no effective outpatient therapies. Poor weight gain in hyperemesis gravidarum is associated with several adverse fetal outcomes including preterm delivery, low birthweight, small for gestational age, low 5-minute Apgar scores, and neurodevelopmental delay. Gabapentin is most commonly used clinically for treating neuropathic pain but also substantially reduces chemotherapy-induced and postoperative nausea and vomiting. Pregnancy registry data have shown maternal first-trimester gabapentin monotherapy to be associated with a 1.2% rate of major congenital malformations among 659 infants, which compares favorably with the 1.6% to 2.2% major congenital malformation rate in the general population. Open-label gabapentin treatment in hyperemesis gravidarum was associated with reduced nausea and vomiting and improved oral nutrition. OBJECTIVE: This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum. STUDY DESIGN: A double-blind, randomized, multicenter trial was conducted among patients with medically refractory hyperemesis gravidarum requiring intravenous hydration. Patients were randomized (1:1) to either oral gabapentin (1800-2400 mg/d) or an active comparator of either oral ondansetron (24-32 mg/d) or oral metoclopramide (45-60 mg/d) for 7 days. Differences in Motherisk-pregnancy-unique quantification of nausea and emesis total scores between treatment groups averaged over days 5 to 7, using intention-to-treat principle employing a linear mixed-effects model adjusted for baseline Motherisk-pregnancy-unique quantification of nausea and emesis scores, which served as the primary endpoint. Secondary outcomes included Motherisk-pregnancy-unique quantification of nausea and emesis nausea and vomit and retch subscores, oral nutrition, global satisfaction of treatment, relief, desire to continue therapy, Nausea and Vomiting of Pregnancy Quality of Life, and Hyperemesis Gravidarum Pregnancy Termination Consideration. Adjustments for multiple comparisons were made employing the false discovery rate. RESULTS: A total of 31 patients with hyperemesis gravidarum were enrolled from October 2014 to May 2019. Among the 21 patients providing primary outcome data (12 assigned to gabapentin and 9 to the active comparator arm), 18 were enrolled as outpatients and all 21 were outpatients from days 5 to 7. The study groups' baseline characteristics were well matched. Gabapentin treatment provided a 52% greater reduction in days 5 to 7 baseline adjusted Motherisk-pregnancy-unique quantification of nausea and emesis total scores than treatment with active comparator (95% confidence interval, 16-88; P=.01). Most secondary outcomes also favored gabapentin over active comparator treatment including 46% and 49% decreases in baseline adjusted Motherisk-pregnancy-unique quantification of nausea and emesis nausea (95% confidence interval, 19-72; P=.005) and vomit and retch subscores (95% confidence interval, 21-77; P=.005), respectively; a 96% increase in baseline adjusted oral nutrition scores (95% confidence interval, 27-165; P=.01); and a 254% difference in global satisfaction of treatment (95% confidence interval, 48-459; P=.03). Relief (P=.06) and desire to continue therapy (P=.06) both showed trends favoring gabapentin treatment but Nausea and Vomiting of Pregnancy Quality of Life (P=.68) and Hyperemesis Gravidarum Pregnancy Termination Consideration (P=.58) did not. Adverse events were roughly equivalent between the groups. There were no serious adverse events. CONCLUSION: In this small trial, gabapentin was more effective than standard-of-care therapy for reducing nausea and vomiting and increasing oral nutrition and global satisfaction in outpatients with hyperemesis gravidarum. These data build on previous findings in other patient populations supporting gabapentin as a novel antinausea and antiemetic therapy and support further research on gabapentin for this challenging complication of pregnancy.
引用
- Guttuso T, Messing S, Tu X, et al. Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. Am J Obstet Gynecol MFM. 2020. PMID: 33451591. doi:10.1016/j.ajogmf.2020.100273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。